Business Context and Reporting Period
This Form 8-K was filed by PerkinElmer, Inc. (noted as REVVITY, INC. in metadata) on October 20, 2011. The report details a significant capital raising event and a strategic acquisition.
Key Financial Metrics
- Debt Issuance: $500 million aggregate principal amount of 5.00% Senior Notes due 2021.
- Net Proceeds: Approximately $490.6 million after underwriting discounts and estimated offering expenses.
- Acquisition Cost: The acquisition of Caliper Life Sciences, Inc. is estimated at approximately $600 million, net of acquired cash.
Material Changes
The primary material change is the entry into an underwriting agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated and Barclays Capital Inc. to issue the Senior Notes. This transaction represents a new long-term debt obligation and a shift in the company's capital structure to fund the Caliper Acquisition.
Outlook and Management Commentary
Management intends to use the net proceeds from the offering to fund part of the consideration for the Caliper Acquisition and to pay associated costs. If the acquisition is not consummated or if proceeds remain after closing, the company plans to use the funds for general corporate purposes. The Notes are issued pursuant to an indenture dated October 25, 2011, with U.S. Bank National Association as trustee.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds of the $500 million Senior Notes offering.
- Confirm the consummation of the Caliper Life Sciences, Inc. acquisition and the final purchase price.
- Review the full Underwriting Agreement (Exhibit 1.1) for covenants and redemption terms.
- Assess the impact of the new 5.00% debt on the company's leverage ratios and interest coverage.